Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|August 2, 2012
- Pharmaceutical Technology-08-02-2012
- Volume 36
- Issue 8
Pharmaceutical Technology, August 2012 Issue (PDF)
Measuring Growth - Big Pharma's Manufacturing Investments
Advertisement
Articles in this issue
about 14 years ago
Q&A with Babu Padmanabhan, STEER Engineeringabout 14 years ago
The Truth About Drug Shortagesabout 14 years ago
Report from Japanabout 14 years ago
Pharmaceutical-Based Cargo Security and Theft Preventionabout 14 years ago
Scaling up API Synthesesabout 14 years ago
Small Changes, System-Wide Impactabout 14 years ago
Measuring Growth in Big Pharma's Manufacturing Investmentabout 14 years ago
Gauging Biopharm Outsourcingabout 14 years ago
In the Spotlight August 2012about 14 years ago
FDA User-Fee Legislation Sets Stage for ChangeAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement